Andre Turenne, Voyager CEO
February 2, 2021 05:07 PM ESTUpdated February 3, 06:27 AM
Pharma

Neu­ro­crine ax­es Parkin­son's col­lab with Voy­ager af­ter safe­ty is­sues, jeop­ar­diz­ing biotech's long-run­ning cen­ter­piece

Jason Mast

Editor

Six years ago, Third Rock Ven­tures launched Voy­ager Ther­a­peu­tics with $45 mil­lion and a goal of bring­ing gene ther­a­py in­to some of the most no­to­ri­ous …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times